The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:
* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.
* To identify the optimal length of anticoagulation in the treatment of LV Thrombus
After randomisation participants will:
* Continue their prescribed oral anticoagulant for the remainder of the trial
* Discontinue their prescribed oral anticoagulant for the remainder of the trial

Start Date01 Dec 2026

Sponsor / Collaborator

Queen Mary University of London

NCT05900388

/ Not yet recruitingNot Applicable

Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
VTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.
Rivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information.
The purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.
The main information that researchers will collect in this study:
* Age, gender, and other information about the child and their illness
* Type of VTE treatment given to the child
* Occurrence of medically important bleeding and its severity
Further information that researchers will collect:
* Changes in the characteristics of the children given VTE treatment (e.g., changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE
* Return of VTE symptoms
* Types of doctors who prescribe VTE treatment and their set-up (e.g., special clinics versus hospitals) Besides this data collection, no further tests or examinations are needed in this study.
The data for this study will be collected from electronic health records and health insurance claims data until 2026.
Researchers will observe each child during treatment until:
* end of the anticoagulation treatment period e.g. discontinuation of all study drugs,
* their information is no longer available, or
* the study ends.

Start Date01 Sep 2026

Sponsor / Collaborator

Bayer AG

[+1]

NCT07318610

/ RecruitingPhase 3

A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants With Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)

This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet.
The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo.
The study is looking at several other research questions, including:
* What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)
* If the study drugs affect the ability of the blood to clot normally

Start Date30 Jul 2026

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

100 Clinical Results associated with Rivaroxaban

100 Translational Medicine associated with Rivaroxaban

100 Patents (Medical) associated with Rivaroxaban

8,440

Literatures (Medical) associated with Rivaroxaban

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Plain language summary examining clinical event related costs associated with changing medication from apixaban to rivaroxaban in people with non-valvular atrial fibrillation in the USA and Germany

Article

Author: Dworatzek, Elke ; Duan, Cecilia ; Kongnakorn, Thitima ; Zhang, Michelle ; Hines, Dionne M. ; Subash, Rupesh ; Kisser, Agnes

31 Dec 2026·RENAL FAILURE

Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis

Review

Author: Liu, Xin ; Meng, Jie ; Zhou, Yilun ; Wu, Xiaoyuan ; Yang, Yu ; Sheng, Dacheng

This study aimed to evaluate the comparative efficacy and safety of apixaban and rivaroxaban versus vitamin K antagonists (VKAs) in anticoagulation management in a dialysis population. PubMed, Embase, and the Cochrane Library were searched for studies comparing apixaban or rivaroxaban with VKAs in patients with atrial fibrillation (AF) undergoing dialysis. The primary efficacy endpoints included stroke/systemic embolism (SSE) and all-cause mortality. Safety outcomes encompassed major bleeding, intracranial hemorrhage, and gastrointestinal bleeding. Risk ratios (RR) with 95% confidence intervals (CI) were synthesized using random-effects models. The meta-analysis included three randomized controlled trials (RCTs) and eight observational studies. Pooled analyses showed that apixaban and rivaroxaban were associated with lower risks of major bleeding (RR 0.57, 95% CI: 0.51-0.63), gastrointestinal bleeding (RR 0.66, 95% CI: 0.57-0.76), and intracranial hemorrhage (RR 0.54, 95% CI: 0.36-0.83) compared with VKAs. Additionally, apixaban and rivaroxaban were associated with reduced risk of SSE (RR 0.57, 95% CI: 0.46-0.72) and all-cause mortality (RR 0.73, 95% CI:0.63-0.83), although substantial heterogeneity was present. Exploratory dose-stratified analyses suggested both standard- and low-dose apixaban regimens were associated with favorable efficacy and hemostatic safety relative to warfarin. Consistent numerical trends were observed in the RCT-only analysis, though none reached statistical significance owing to limited sample size. In conclusion, apixaban and rivaroxaban are associated with lower risks of bleeding compared with VKAs in patients with AF and ESRD. However, evidence regarding their efficacy in preventing SSE, all-cause mortality and the optimal apixaban dosing regimen remains inconclusive and requires validation in large, dedicated RCTs.

15 Aug 2026·RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Microcolumn Liquid Chromatography-Atmospheric Pressure Chemical Ionisation Tandem Mass Spectrometric Determination of Nitrosamine Impurities From Pharmaceutical Products.

Article

Author: Krishna, Maloth Rama ; Nagaraju, Maddala ; Kanakala, Satya Sri Dharmika ; Upadhyayula, Vijayasarathi V R ; Harlikar, Jayvant ; Shendage, Sanjay K

RATIONALE:

Pharmaceutical analysis is vital for assessing drug quality and identifying impurities. The recent emergence of carcinogenic nitrosamine contaminants has escalated scrutiny, resulting in the withdrawal of multiple medications. This study focuses on developing robust analytical techniques to detect specific nitrosamine impurities in anticoagulant drugs (Apixaban, Rivaroxaban) and antidepressant drugs (Duloxetine HCl) while enhancing the eco-friendliness of the method.

METHODS:

Nitrosamines were separated on a microbore liquid chromatographic column, and their concentrations were determined using a liquid chromatography system coupled to a triple quadrupole tandem mass spectrometer in positive/negative mode with atmospheric pressure chemical ionisation.

RESULTS:

The results showed good separation of analytes with sensitivities reaching the required standards. The method was validated as per ICH Q2(R2) guidelines. The linearity of the method was performed from 0.1 ng/g to 5 μg/g quantity of the nitrosamines. The obtained calibration curves showed excellent linearity with the square of regression coefficient ranging from 0.994 to 0.998. The determination accuracy ranged from 85.53% to 119.55%, with a relative standard deviation of 2.3% to 8.1%. The interday and intraday precisions were less than 10%. The findings illuminate intricate relative uncertainties ranging from 18.2% to 29.5% across three drug products. Regarding sustainability, the method scored 69 on the GAPI assessment and 0.67 on the AGREE assessment, indicating moderately green.

CONCLUSION:

This validated method provides sensitivity and precision in detecting nitrosamine impurities in the selected pharmaceutical products in the limits specified by various pharmacopeias and compliant with ICH Q2 (R2) standards. The solvent consumption is relatively very low compared with that of the reported standard methods; hence, the method becomes environmentally friendly and economical.

361

News (Medical) associated with Rivaroxaban

20 Jul 2026

·www.prnewswire.com

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

PRINCETON, N.J., July 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2026 financial results and recent business highlights after the market close on Thursday, August 6, 2026. CytoSorbents' management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30PM ET the same day. Conference Call and Webcast Details: Date: Thursday, August 6, 2026 Time: 4:30 PM ET Live webcast link: It is recommended that participants dial in approximately 10 minutes prior to the start of the call. An archived recording of the conference call will be available under the Investor Relations section of the Company's website at About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorbents' lead product, CytoSorb ®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb® was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb® has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb® is not yet approved or cleared in the United States. In the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb®, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb®, ContrastSorb, and others. For more information, please visit the Company's website at and follow us on Facebook and X and LinkedIn. Forward-Looking Statements This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, the impact of geopolitical events including the recent war in Iran, our ability to successfully obtain U.S. FDA and Health Canada regulatory approval and marketing authorization, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve operating cash-flow break-even in the second half of 2026, our ability to appropriately finance the Company, including our ability to meet our financial obligations and comply with the covenants under our existing debt agreement,, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. Please Click to Follow Us on Facebook and X U.S. Company Contact: Peter J. Mariani, Chief Financial Officer 305 College Road East Princeton, NJ 08540 [email protected] SOURCE Cytosorbents Corp 21% more press release views with Request a Demo

Drug ApprovalBreakthrough TherapyFinancial Statement

01 Jun 2026

·www.biospace.com

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)

FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto ® . Rivaroxaban is a direct oral anticoagulant prescribed to treat and prevent deep vein thrombosis and pulmonary embolism. It is also widely utilized to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The global market for Rivaroxaban is estimated to reach $12.7 Billion in 2026 and is set to expand to approximately $30.5 Billion by 2035, growing at a CAGR of 10.19% during the forecast from 2026 to 2035, ( Business Research Insights ). According to IQVIA Pharmafocus 2028 , the Canadian pharmaceutical market accounts for approximately 2.1% of the global pharmaceutical market and ranks as the 6th largest worldwide. Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma Inc. The addition of Rivaroxaban to our portfolio of drugs represents a strategic expansion for the Company in the area of anticoagulants. The Company's first generic anticoagulant, Apixaban (brand name Eliquis ® ) has been on the market for over three years. It is anticipated that Sunshine Biopharma's Rivaroxaban will be ready to ship to pharmacies in October 2026. "We are pleased to introduce Rivaroxaban oral tablets as the newest addition to our expanding portfolio of high-quality generic drugs," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This approval strengthens our position in the generics market and reflects our ongoing commitment to delivering affordable medicines that patients and healthcare providers can rely on." About Sunshine Biopharma Inc. Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: . All registered trademarks are the property of their respective owners. Safe Harbor Forward-Looking Statements This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings. For more information, please contact: Camille Sebaaly, CFO Direct Line: 514-814-0464 camille.sebaaly@sunshinebiopharma.com SOURCE : Sunshine Biopharma Inc. View the original press release on ACCESS Newswire

Drug Approval

21 May 2026

·www.fiercepharma.com

Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear

Sales in the biopharma industry trended up in the first quarter of this year as eight of the biopharma industry’s top-25 companies had double-digit year-over-year growth, with Eli Lilly outdistancing the field with a 56% sales increase. Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth, which was an uptick from a year ago. By comparison, in each of the four quarters of 2025, there were six drugmakers that had double-digit gains.In addition to juggernaut Eli Lilly (+56%), which has led the growth rankings each of the last six quarters, Regeneron (+19%), AstraZeneca (+13%), AbbVie (+12%), Sandoz (+11%) and Johnson & Johnson (+10%) accomplished double-digit growth in the first quarter of the year. Also pulling off the feat were Japanese drugmakers Astellas (+17%) and Daiichi Sankyo (+13%). Regeneron’s performance came after a year in which its sales grew by just 1% during the first quarter. Regeneron’s growth was its highest for a quarter since 2021, when sales spiked behind coronavirus antiviral REGEN-COV. Leading the way for Regeneron in Q1 was Sanofi-partnered Dupixent, which has seen a recent boost thanks in part to recent label expansions to treat COPD, urticaria and bullous pemphigoid. Dupixent sales were up 33% to $4.9 billion in Q1, helping the company overcome a 10% decline for Eylea, which saw its sales fall to below $1 billion for a quarter for the first time since 2018. AstraZeneca returned to double-digit growth in the first quarter after seeing sales increase by just 4% in the previous period. Doing the heavy lifting were AZ’s oncology and rare disease portfolios, which were up 20% and 19%, respectively. The company’s deep roster of medicines has put it in position to thrive for several years. In the quarter, AZ had 15 products that generated at least $300 million and thus are on track to achieve blockbuster sales this year. Of these, nine had double-digit growth in Q1 and only one of the 15 saw a decline in sales.AbbVie had its second straight quarter of double-digit growth. The last time the Illinois company put two double-digit quarters together was in 2021, when its immunology superstar Humira was in its prime. After four straight quarters of sales declines in 2023 as Humira faced biosimilar competition, AbbVie has recovered behind Skyrizi and Rinvoq. The duo generated a combined $6.6 billion in the first quarter, up from $5.1 billion a year ago. The $1.5 billion boost in the two immunology medicines accounted for nearly all of the company’s increase from quarterly revenue of $13.3 billion in Q1 of 2025 to $15.0 billion in 2026. Sandoz rode the success of its biosimilars portfolio, which was up by 27% to $853 million for the quarter thanks to a strong performance from Humira biosimilar Hyrimoz and the launches of Eylea knockoff Afqlir and Xgeva, plus Prolia copycats Wyost and Jubbonti.The first quarter performance for Johnson & Johnson was a milestone as it had not reached double-digit growth in a quarter since the pandemic, when it briefly sold its ill-fated COVID-19 vaccine. Divesting its consumer health unit Kenvue in 2023 has helped J&J achieve a higher growth rate. In Q1, J&J compensated for a steep falloff in sales of Stelara from $1.6 billion to $656 million, with big performances by cancer drug Darzalex and immunology standout Tremfya. While Darzalex drew sales of $4 billion, which were up 23%, Tremfya’s haul increased by 68% to $1.6 billion. With the results, J&J increased its annual revenue projection by $300 million at its guidance midpoint of $100.8 billion.Astellas continued its growth jag, which reached (PDF) 12% for its fiscal year. In FY 2025, Veozah (+37%), Padcev (+35%), Izervay (+33%) propelled the boost, along with prostate cancer treatment Xtandi (+5%), which generated JPY 961 billion ($6 billion) and accounted for 45% of the company’s revenue for the year. Like Astellas, Daiichi Sankyo has shown strong growth in recent years. But after peaking with a 25% revenue increase for FY 2023, the revenue increases for the ADC powerhouse have slowed, from 17% in FY 2024, to 13% in 2025 and to a projected (PDF) figure of 7% in FY 2026. During its quarterly presentation earlier this month, Daiichi unveiled a 5-year plan to become one of the top five oncology companies in the industry and established a goal to reach sales of 3 trillion yen ($19.1 billion) in 2030, up from 2.1 trillion yen ($13.2 billion) in FY 2025.Nearly making it to the double-digit group was Viatris, which had a 9% sales increase in Q1, providing another signal of its turnaround after revenue declines in each of the previous four years. After the company was formed though a merger of Mylan and Pfizer’s former generics unit Upjohn in 2020, it stripped down through divestitures and now is anticipating consistent revenue growth to the end of the decade. No slowdown for Lilly Eli Lilly’s presence at No. 1 was expected. The Indianapolis drugmaker has led the industry growth rankings in each of the last six quarters. But its 56% growth rate was an eye-opener, as it topped the analyst consensus estimate by 13%.It was the highest quarterly sales increase for the company during its tirzepatide era, which began with the 2022 approval of Mounjaro. The diabetes treatment was the heavy lifter in Q1, with its sales increasing 125% to $8.7 billion, while obesity drug Zepbound pulled in $4.2 billion for an 80% increase.With the Q1 results, Lilly jacked up its 2026 revenue projection by $2 billion to a window of $82 billion to $85 billion. Increasing its annual estimates has become a quarterly routine for Lilly, which opened 2025 with sales guidance at between $58 billion and $61 billion and closed the year with revenue topping $65 million. Lilly’s competitor in the GLP-1 market, Novo Nordisk, continued its slide with sales declining by 10%. It was the largest sales decline in the industry in Q1 and the second straight quarter in which Novo was at the bottom of the top-25 growth rankings. There were positive signs from Novo, however, as its share price increased by 3% with its quarterly report, which included sales of its new obesity pill Wegovy coming in at $355 million.“The Wegovy pill is off to a record-breaking start in the U.S.,” Novo CEO Doustdar said on a May 6 analyst call. “Since launching it some 16 weeks ago, we have seen over one million people using Wegovy pill as the global momentum behind the peptide-based therapy accelerates.”Baking in the higher expectations for its GLP-1 products, Novo has adjusted its forecast for the year, expecting sales to work out to a 4%-to-12% decline, slightly softer than the 5%-to-13% decline the company guided to in February. Other decliners in Q1 Sales for Novartis were down (PDF) by 1% in the first quarter, owed largely to generic competition for Entresto, which hit in the U.S. in July of last year. Revenue from the heart failure medicine plummeted from $2.3 billion in the first quarter of 2025 to $1.3 billion in this year’s first quarter. The overall decline for Novartis comes after it saw revenues increase by 12% in 2024 and 8% last year.Bayer, which is also facing generic and biosimilar competition for blood thinner Xarelto and eye disease drug Eylea, saw a 7% slide in sales in the quarter from combined sales of its pharma and consumer health units. The conglomerate expects the effects to subside in the second half and set the pharma division up for growth in 2027. Roche had a 5% revenue decline in the first quarter, when tabulating sales in Swiss francs. At constant exchange rates, however, the company’s sales were up 6%.

VaccineAcquisitionBiosimilarFinancial StatementDrug Approval

100 Deals associated with Rivaroxaban

External Link

KEGG	Wiki	ATC	Drug Bank
D07086	Rivaroxaban	B01AF01	DB06228

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Coronary Disease	United States	Janssen Pharmaceuticals, Inc.	24 Mar 2026
Thromboembolism	Japan	Bayer Yakuhin Ltd.	24 Nov 2023
Thrombosis	United States	Janssen Pharmaceuticals, Inc.	20 Dec 2021
Atherosclerosis	European Union	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Iceland	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Liechtenstein	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Norway	Viatris Ltd. (New Zealand)	12 Nov 2021
Atrial Fibrillation	China	Bayer AG	31 Mar 2009
Myocardial Infarction	Australia	Bayer Australia Ltd.	24 Nov 2008
Recurrent deep vein thrombosis	Australia	Bayer Australia Ltd.	24 Nov 2008
Stroke	Australia	Bayer Australia Ltd.	24 Nov 2008
Systemic embolism	Australia	Bayer Australia Ltd.	24 Nov 2008
Acute Coronary Syndrome	European Union	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Iceland	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Liechtenstein	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Norway	Bayer AG	30 Sep 2008
Embolism	European Union	Bayer AG	30 Sep 2008
Embolism	Iceland	Bayer AG	30 Sep 2008
Embolism	Liechtenstein	Bayer AG	30 Sep 2008
Embolism	Norway	Bayer AG	30 Sep 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 3	Australia	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Belgium	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Canada	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	France	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Germany	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	India	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Malaysia	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Nepal	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Saudi Arabia	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Singapore	Bayer AG	18 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03266783 (COBRRA, CTgov)	Phase 4	Hemorrhage \| Venous Thromboembolism	2,760	Apixaban (Apixaban Group)	sofxzpvfhw = ozqlhncote szaepflbjc (rblgvcbpkv, wftmezjpzm - hlpgjonlkq) View more	-	24 Jun 2026
				rivaroxaban (Rivaroxaban Group)	sofxzpvfhw = zufvgtglcl szaepflbjc (rblgvcbpkv, wkgylzathf - krorqpkfya) View more
ADA2026	Not Applicable	Atrial Fibrillation	369,480	Reduced-Dose Direct Oral Anticoagulants	aqvljxpmfo(vdlptyyhes): HR = 1.13, P-Value = 0.04	Positive	20 Jun 2026
				Standard-Dose Direct Oral Anticoagulants
NCT03969953 (Pubmed \| JAMA)	Phase 3	Kidney Diseases	1,458	Rivaroxaban 2.5 mg	ukgsmwdhuu(splihplrvf) = edchyoqgrv vgyeyckrij (noyneaaunb ) View more	Negative	04 Jun 2026
				Placebo	ukgsmwdhuu(splihplrvf) = qgeqvfvefx vgyeyckrij (noyneaaunb ) View more
NCT03746275 (XATOA, Pubmed \| Drugs Context)	Not Applicable	Coronary Artery Disease \| Peripheral Arterial Disease	311	Rivaroxaban 2.5 mg twice daily + Aspirin	zprihwvvdi(uhtfhnqojd) = yggeuipphb fteevgcgtf (kzpszrmkbz ) View more	Positive	02 Jun 2026
NCT06901466 \| NCT07007143 (STAR-TEER, Pubmed \| Am Heart J)	Phase 4	Mitral Valve Insufficiency	1,912	Rivaroxaban plus clopidogrel (Requiring long-term OAC)	xggatcrwbl(jljzfoifee) = blbkqrruzn iepdofcwbc (fxekgifjvw )	Positive	01 Jun 2026
				Aspirin plus clopidogrel (No OAC indication)	xggatcrwbl(jljzfoifee) = jughnprkhu iepdofcwbc (fxekgifjvw )
ASCO2026	Not Applicable	Venous Thromboembolism hemoglobin \| thrombocytopenia \| CKD ... View more	11,380	Apixaban 5 mg	vldzjzewjy(xkztrthwqm) = zlrycgwngm nczqxquynr (qldlfydpdi ) View more	Similar	29 May 2026
				Rivaroxaban 20 mg	vldzjzewjy(xkztrthwqm) = dqvksprbkm nczqxquynr (qldlfydpdi ) View more
NCT03702582 (NEW-AF, CTgov)	Phase 3	Hemorrhage \| Stroke \| Atrial Fibrillation	100	Warfarin (Warfarin)	pdaekohwzp(hzwdfzolpx) = junkwodsbo jjuftlwiie (xaircutwwl, cnxtedrqdg - ukqybfvhsj) View more	-	19 May 2026
				rivaroxaban (Rivaroxaban)	pdaekohwzp(hzwdfzolpx) = urkwnsmxfp jjuftlwiie (xaircutwwl, spmlaajlfg - ynvqfyjomd) View more
EHA2026	Not Applicable	Atrial Fibrillation \| Venous Thromboembolism	200	Apixaban 5 mg twice daily	iqbzzpsgug(tdodjexzzh) = zopihololh owetbunqvm (umqnmpolun ) View more	Positive	12 May 2026
				reduced DOAC doses	iqbzzpsgug(tdodjexzzh) = cknspsvvwj owetbunqvm (umqnmpolun ) View more
NCT02504216 (VOYAGER-PAD, Pubmed \| Circ Cardiovasc Interv)	Phase 3	Peripheral Arterial Disease	6,564	Rivaroxaban 2.5 mg + Rivaroxaban 2.5 mg	sgdkzhptik(zwmoftbnoh) = wxqbxbhhbm frxupsfzzq (wvxucznvyv )	Positive	01 May 2026
				Placebo + Aspirin 100 mg	sgdkzhptik(zwmoftbnoh) = ahmmwsqyvx frxupsfzzq (wvxucznvyv )
NCT05077683 (FRENCHIE, Pubmed \| JAMA Cardiol)	Phase 3	Thrombosis	560	DAPT plus rivaroxaban	vgxpsmeplh(qicxgkjfqb) = ohqmgcmgym migdowqnef (pvlxpscgbv ) View more	Negative	01 Apr 2026
				DAPT	vgxpsmeplh(qicxgkjfqb) = kgbbgdjjdk migdowqnef (pvlxpscgbv ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis